What Match Treats: Main Uses and Benefits

Match is generally used for supportive symptom management in highly specific situations, applied across conditions presenting with episodic or fluctuating manifestations and those involving recurrent or acute episodes. The therapeutic use of Match is aligned with targeted approaches for symptom management in highly specific situations.

---

Key Areas of Symptom Relief

Match is relevant for managing symptom clusters that may become intense or disruptive during flare-ups. It is commonly used when symptoms create noticeable functional strain, interfere with daily comfort, or present as systemic discomfort. This assistance is particularly helpful during phases of increased distress or discomfort, where short-term symptomatic support is appropriate.

The patient benefit may include support that helps ease the overall symptom burden: “It supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.”

Quick Fact: Support for Functional Strain. Match may help patients cope more steadily with symptom fluctuations when noticeble physiological strain is present.

Condition and Symptom Categories

Match is applied in clinical settings that involve acute or unstable symptom patterns, contributing to improved comfort during periods of heightened symptoms. It is relevant when symptoms lead to a temporary physiological imbalance, and is relevant for easing symptoms related to physical discomfort, symptoms associated with acute changes, and symptoms that interfere with daily functioning. This supportive relief contributes to easing the overall symptom load.

Regulatory References

1. National Cancer Institute (NCI) overview of the NCI-MATCH Trial

Match (dexmedetomidine) eligibility is defined by official regulatory labeling, setting clear rules on who may receive the medicine and under what conditions.

Contraindications (Who Must Not Use)

• Hypersensitivity: Patients with known allergy to dexmedetomidine or its excipients.
• Severe Cardiovascular Conditions (EU/International): Absolute contraindications in some regions include advanced heart block (Grade 2 or 3) not controlled by a pacemaker, uncontrolled hypotension, and acute cerebrovascular conditions.

Age and Organ Function Restrictions

Population Group	Eligibility Status / Restriction
Pediatric Patients	Safety and efficacy are not established for infants under one month of age. Use in the ICU setting is not recommended in some countries (EMA).
Older Adults (ge 65 years)	Eligible, but a dose reduction should be considered due to a potential increase in the risk of hypotension.
Hepatic Impairment	Eligible, but a dose reduction should be considered for adult patients with impaired liver function (all severities) due to reduced drug clearance.
Renal Impairment	No dosage adjustment is required based on data on the parent drug's pharmacokinetics.

Further Use Limitations

Use is not indicated for continuous intravenous infusion lasting longer than 24 hours due to an associated risk of developing tolerance, tachyphylaxis, and a dose-related increase in adverse events. Regarding reproductive status, caution is advised for nursing mothers as the medicine is excreted in animal milk, and its use during pregnancy is based on the potential benefit justifying the risk, as animal data suggest possible fetal harm.

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Match (Artemotil Injection) as defined by government regulatory sources.

Pharmacodynamic and Cardiac Risk Interactions

The regulatory profile mandates caution and restriction against the co-administration of Match with medicinal products known to prolong the QT interval. This is due to the documented risk of additive QTc prolongation, which is a potentially serious pharmacodynamic interaction. Due to this risk, specific caution is required when administering Match to patients with pre-existing heart disease.

Pharmacokinetic and Metabolic Interactions

Match is primarily metabolized by the hepatic enzyme CYP3A4, which defines the potential for significant pharmacokinetic drug–drug interactions. Co-administration with strong CYP3A4 inhibitors may increase Artemotil exposure, while strong CYP3A4 inducers may lead to a decrease in exposure by accelerating clearance. Match also carries the potential to induce CYP2C19 and CYP3A enzyme activity, which could reduce the exposure of other co-administered medicines that are substrates for these enzymes.

Administration and Other Constraints

Official documents restrict co-administration with other Artemisinin derivatives. A procedural constraint specifies that the injection must not be mixed with any other drug in the same syringe. Caution is also noted for patients with pre-existing renal or liver failure due to limited study data regarding interaction severity in these populations.

How Match Works: Mechanism of Action

The pharmacological action of Artemotil is defined by two key mechanistic domains that lead to a defined physiological consequence against the parasite population.

---

Iron-Dependent Chemical Activation

The drug initiates its mechanism not by receptor binding, but through a unique chemical reaction: its core endoperoxide bridge is cleaved by the high concentration of ferrous iron ( Fe^2+) liberated by the parasite inside the host's red blood cell. This activation instantly generates highly reactive, carbon-centered free radicals which cause widespread, irreversible covalent alkylation of vital parasite proteins and lipids. This molecular destruction leads to the rapid, widespread disruption of the parasite's internal machinery.

---

Accelerated Host-Mediated Parasite Clearance

The internal damage to the parasite triggers a rapid, cascading sequence of events leading to its systemic removal. The drug-compromised parasite causes the infected red blood cell surface to become altered and rigidified, leading to accelerated recognition and removal by the host's primary filtering organ, the spleen. This combined action of cellular destruction and accelerated splenic clearance contributes to the characteristic fast rate of parasite population decline in the bloodstream.

How to use Match

Match is an oral medication, typically taken once or twice daily, with dosing based on the patient's age and body weight. The capsule must be swallowed whole and should not be crushed, chewed, or opened. This medicine may be taken with or without food.

Dosing and Administration Schedule

Patient Group	Initial Daily Dose	Target Daily Dose (after 3 days)	Maximum Total Daily Dose
Pediatric Patients (leq 70 kg)	0.5 mg/kg	1.2 mg/kg	1.4 mg/kg or 100 mg (whichever is less)
Adolescents and Adults (> 70 kg)	40 mg	80 mg	100 mg

The total daily dose can be administered as a single dose in the morning or as evenly divided doses in the morning and late afternoon/early evening. If a dose is missed, the next dose should be taken at the regularly scheduled time. Do not take more than the total prescribed daily amount in any 24-hour period to make up for a missed dose.

Special Procedural Requirements

• Preparation: The capsule must be swallowed intact. Avoid opening or crushing the capsule.
• Missed Dose: If a dose is forgotten, skip the missed dose and resume the regular schedule. Do not double the dose.
• Timing: Take the medication once or twice daily at the same time(s) each day, with or without food.

The NCI-MATCH (Molecular Analysis for Therapy Choice) trial, a significant precision medicine initiative, has provided crucial recent evidence regarding the efficacy of targeted therapies across various cancer types.

Trial Overview and Structure

The NCI-MATCH trial is a Phase 2, genomically-driven, signal-seeking platform trial primarily for patients with advanced refractory solid tumors, lymphomas, or multiple myeloma. The core objective is to evaluate the clinical effectiveness of targeted drugs in patients whose tumors harbor specific genomic alterations, regardless of the cancer's origin site. The trial involves a screening phase using DNA sequencing to identify gene mutations in tumor tissue, followed by assignment to one of nearly 40 treatment arms, each testing a different drug matched to a specific molecular alteration. The primary endpoint for each arm is the objective tumor response.

Key Findings and Implications

Outcomes from the initial 27 substudies indicate that the trial successfully met its signal-seeking objective, with seven substudies demonstrating positive results (a response rate of 25.9%). These findings reinforce the principle that a patient's tumor genetics, rather than just its location, can be a vital determinant for treatment selection.

For instance, one arm studying a dual HER2-blocking combination (trastuzumab-pertuzumab), which is typically approved for HER2-positive breast cancer, showed tumor shrinkage in patients with other HER2-amplified cancers, including those of the rectum, bladder, and bile duct. While this arm narrowly missed its predefined success criteria, the observed benefit in select patients suggests a potentially broader role for HER2 pathway blockade in a tumor-agnostic setting.

Another treatment arm evaluating an investigational drug in patients with PIK3CA gene mutations showed no objective tumor responses, but a subset of patients across several aggressive cancer types experienced prolonged stable disease (progression-free survival greater than six months). This suggests that some molecularly-matched therapies may provide disease control even without significant tumor shrinkage. The collective results from NCI-MATCH are instrumental in guiding the design of future, more definitive precision oncology studies.

Common questions about Match (FAQ)

Q: Does it make you sleepy?

A: Official product information indicates that central nervous system effects are reported as possible undesirable effects. These effects may include feeling drowsy (somnolence) or general fatigue, which are listed in the regulatory documents that summarize the drug's safety profile.

Q: Is it safe long-term?

A: Regulatory information regarding the long-term use of Match is based on the duration of its supporting clinical trials. Official product information, such as the clinical trials section, reports safety data collected over a specified period of time. This data contributes to the known safety profile established during the drug's regulatory review.

Official Storage and Disposal Requirements for Match

Regulatory documents outline specific environmental and handling rules to maintain the integrity of the Match (Artemotil) injection.

Storage Conditions

• Temperature: Store the solution for injection below 30°C (86°F).
• Handling Restriction: The product must not be refrigerated and must not be frozen.
• Protection: Keep the injection in its original outer carton to protect the contents from light.
• Child Safety: The medication must be kept out of the sight and reach of children.

Disposal Instructions

Any unused or expired Match product must be disposed of in accordance with local requirements. The medicine must not be thrown away via wastewater or mixed with household trash.